<DOC>
	<DOCNO>NCT00957034</DOCNO>
	<brief_summary>Heart failure ( HF ) complex condition result structural functional heart diseases impair ability heart fill pump blood . The main manifestation HF shortness breath tiredness may limit ability exercise perform simple daily physical activity walk . Heart disease lead HF associate reduced muscle mass reduce strength low blood level testosterone ; hormone normally produce human ( male female ) body . Recent study show improvement symptom ability exercise patient heart failure receive testosterone . This placebo control study determine efficacy safety low dose testosterone ( 300 450 microgram/day ) deliver transdermal system ( patch ) woman significant HF .</brief_summary>
	<brief_title>Assessing Safety/Efficacy Transdermal Testosterone Female Patients With Symptomatic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Female 50 year age old ; postmenopausal ( â‰¥ 12 Mo/ last menstruation ) Documented left ventricular ejection fraction ( LVEF ) 2040 % within 90 day prior baseline visit History HF 90 day diagnosis symptomatic HF ( Class III NYHA ) least 30 day prior baseline visit Ambulatory ( i.e. , able walk without assistance another person device cane walker ) Neuromuscular rheumatologic condition limit ability improve walk distance Pulmonary edema multiorgan failure cardiogenic shock within 30 day prior baseline visit Congenital heart disease , infiltrative myocardial disease Unstable angina myocardial infarction within 30 day prior baseline visit Undiagnosed abnormal genital bleed History breast cancer , breast surgery , breast disease contraindicate estrogen/hormone therapy Polycystic ovary syndrome condition know adversely affected testosterone treatment Resting heart rate &gt; 120 bpm Systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 100 mmHg Known suspect hypersensitivity allergy adhesive component testosterone transdermal system ( TTS ) Use SERMS , SARMS , SPRMs , tibolone , testosterone , estrogen , progesterone agonist antagonists take prescription counter medications/ nutraceuticals ( eg , phytoestrogens ) may anabolic steroid hormonal effect within 30 day prior baseline visit Use market investigational oral , sublingual , topical , transdermal injectable , vaginal androgen therapy include dehydroepiandrosterone ( DHEA ) time within 3 month prior baseline visit Use systemic corticosteroid within 30 day prior baseline visit ( acute use few 7 day acceptable )</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>